Cargando…

Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma

Melanoma is a severe and life-threatening malignancy derived from melanocytes. The traditional treatment for melanoma could not sustain satisfactory outcomes long term; however, the recent immune checkpoint treatment has made a breakthrough in these problems. Nivolumab is a representative immune che...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Ryuichi, Sawada, Yu, Nakamura, Motonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920420/
https://www.ncbi.nlm.nih.gov/pubmed/33669410
http://dx.doi.org/10.3390/ijms22041957
_version_ 1783658273211154432
author Saito, Ryuichi
Sawada, Yu
Nakamura, Motonobu
author_facet Saito, Ryuichi
Sawada, Yu
Nakamura, Motonobu
author_sort Saito, Ryuichi
collection PubMed
description Melanoma is a severe and life-threatening malignancy derived from melanocytes. The traditional treatment for melanoma could not sustain satisfactory outcomes long term; however, the recent immune checkpoint treatment has made a breakthrough in these problems. Nivolumab is a representative immune checkpoint treatment, and this PD-1-targeted therapy has evolutionally developed and improved the clinical outcome in a recent decade. On the other hand, the clinical application of immune checkpoint treatment presents clinicians with novel questions, especially how to obtain additional efficacy and overcome the disadvantage by using this treatment. To answer these problems, we first investigated the distribution of PD-L1 in various organs to clarify the organs most affected by anti-PD-1 antibody treatment. Among various organs, lung, placenta, spleen, heart, and thyroid highly expressed PD-L1, while skin, thalamus, hippocampus, ovary, stomach, testis, and prostate showed lower expressions of PD-L1. Furthermore, the immune profiles were also examined in tumors and peripheral blood in patients with melanoma. PD-1 was highly expressed in CD8 and CD4 cells, and B cells also highly expressed PD-1 compared with NK cells. However, there was no significant difference in Th1/Th2/Th17 cytokines and inhibitory cytokine IL-10. Although nevus showed a low expression of PD-L1 compared with healthy skin, PD-L1 expression was increased in growth-phase melanoma. Finally, we analyzed the peripheral blood profiles in patients treated with nivolumab. PD-1-bearing dendritic cells (DCs) were increased during nivolumab treatment and Lin-CD11c+HLA-DR+ cells were highly increased during nivolumab treatment. These findings indicate a clue to answering the problems during nivolumab treatment and suggest to us the importance of multiple aspect observation during immune checkpoint treatment.
format Online
Article
Text
id pubmed-7920420
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79204202021-03-02 Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma Saito, Ryuichi Sawada, Yu Nakamura, Motonobu Int J Mol Sci Article Melanoma is a severe and life-threatening malignancy derived from melanocytes. The traditional treatment for melanoma could not sustain satisfactory outcomes long term; however, the recent immune checkpoint treatment has made a breakthrough in these problems. Nivolumab is a representative immune checkpoint treatment, and this PD-1-targeted therapy has evolutionally developed and improved the clinical outcome in a recent decade. On the other hand, the clinical application of immune checkpoint treatment presents clinicians with novel questions, especially how to obtain additional efficacy and overcome the disadvantage by using this treatment. To answer these problems, we first investigated the distribution of PD-L1 in various organs to clarify the organs most affected by anti-PD-1 antibody treatment. Among various organs, lung, placenta, spleen, heart, and thyroid highly expressed PD-L1, while skin, thalamus, hippocampus, ovary, stomach, testis, and prostate showed lower expressions of PD-L1. Furthermore, the immune profiles were also examined in tumors and peripheral blood in patients with melanoma. PD-1 was highly expressed in CD8 and CD4 cells, and B cells also highly expressed PD-1 compared with NK cells. However, there was no significant difference in Th1/Th2/Th17 cytokines and inhibitory cytokine IL-10. Although nevus showed a low expression of PD-L1 compared with healthy skin, PD-L1 expression was increased in growth-phase melanoma. Finally, we analyzed the peripheral blood profiles in patients treated with nivolumab. PD-1-bearing dendritic cells (DCs) were increased during nivolumab treatment and Lin-CD11c+HLA-DR+ cells were highly increased during nivolumab treatment. These findings indicate a clue to answering the problems during nivolumab treatment and suggest to us the importance of multiple aspect observation during immune checkpoint treatment. MDPI 2021-02-16 /pmc/articles/PMC7920420/ /pubmed/33669410 http://dx.doi.org/10.3390/ijms22041957 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Saito, Ryuichi
Sawada, Yu
Nakamura, Motonobu
Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma
title Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma
title_full Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma
title_fullStr Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma
title_full_unstemmed Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma
title_short Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma
title_sort immune profile analysis in peripheral blood and tumor in patients with malignant melanoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920420/
https://www.ncbi.nlm.nih.gov/pubmed/33669410
http://dx.doi.org/10.3390/ijms22041957
work_keys_str_mv AT saitoryuichi immuneprofileanalysisinperipheralbloodandtumorinpatientswithmalignantmelanoma
AT sawadayu immuneprofileanalysisinperipheralbloodandtumorinpatientswithmalignantmelanoma
AT nakamuramotonobu immuneprofileanalysisinperipheralbloodandtumorinpatientswithmalignantmelanoma